Minimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges

Minimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges

On-Demand Webcast
Faculty

Rafael Fonseca, MD
Mayo Clinic
Phoenix, Arizona

Gail J. Roboz, MD
Weill Cornell Medicine
New York, New York

Target Audience

This activity is intended for hematologists/oncologists, PAs, NPs, nurses, and pharmacists who specialize in hematology, as well as other HCPs who care for patients with hematologic malignancies.

Overview

Information on the role of MRD in other hematologic malignancies is emerging at a rapid pace. Increasing knowledge concerning the utilization of MRD in treatment of various leukemias and lymphomas, its pertinence to drug development, and the refinement of measuring technologies may help to revolutionize treatment paradigms for all hematologic malignancies and allow for dynamic and individualized therapy. Because MRD testing has become consistently and reliably able to detect the existence of malignant cells to within 1 cancerous cell per million cells over the past decade, it is becoming increasingly standardized in the clinical management of patients across many hematologic cancers. Both national and international guidelines and consensus documents have been updated to include the use of MRD in several hematological malignancies and attempt to address questions such as when to test and which testing method to use. The prognostic importance of MRD for high-risk patients has been proven in hematologic malignancies such as ALL, AML, and MM and incorporated into clinical guidelines. However, clinicians face a substantial challenge when it comes to evaluating prognostic significance of MRD on a case-by-case basis.

This webcast aims to fill the gaps in clinician knowledge about the various techniques to detect MRD and their prognostic significance for patients with hematologic malignancies.

Objectives

Upon successful completion of this educational activity, participants should be better able to:

  1. Compare currently-available MRD testing methods and describe their application to discrete hematologic malignancies
  2. Discuss existing guideline recommendations for MRD testing and the various factors that may affect MRD test results
  3. Evaluate the prognostic significance of MRD across the spectrum of hematologic malignancies
  4. Identify potential future applications for MRD in real-world clinical practice
  5. Recognize the significance, technical approaches, and limitations of MRD detection in acute leukemias and develop strategies to use MRD to inform treatment decisions.

Release Date: December 20, 2019

Expiration Date: December 20, 2020

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Support

Supported by an educational grant from: Adaptive Biotechnologies

Accreditation

 In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

PHYSICIANS

NACCME designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHYSICIAN ASSISTANTS

NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 credit(s).

PAs should only claim credit commensurate with the extent of their participation.

CNE

This continuing nursing education activity awards 0.75 contact hours.

CPE

This knowledge-based activity (JA0006201-9999-20-038-H01-P) is approved for 0.75 contact hours (0.075 CEUs) of continuing pharmacy education.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises Rafael Fonseca, MD, Gail J. Roboz, MD; and Chris Bolwell, Lara Gray, and Griselda Zuccarino-Catania Imedex.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME and Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant financial relationships that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME and Imedex to initiate a mechanism to resolve any conflicts. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Rafeal Fonseca, MD, reports that he is a consultant for AbbVie, Aduro, Amgen, Bayer, BMS, Celgene, Janssen, Juno, Kite, Merck, Novartis, Pharmacyclics, Sanofi, and Takeda; and has received other financial support from Adaptive Biotechnologies.

Gail J. Roboz, MD, reports that she is a consultant for AbbVie, Actinium, Agios, Amphivena, Argenx, Astex Astellas, Bayer, Celgene, Celltrion, Daiichi Sankyo, Eisai, Janssen, Jazz, Novartis MEI Pharma, Orsenix, Otsuka, Pfizer, Roche/Genentech, Sandoz, Takeda, and Trovagene; and has received grant or research support from Cellectis.

Chris Bolwell discloses that he holds shares of stock of GlaxoSmithKline.

Griselda Zuccarino-Catania disclosed that her spouse is employed by Janssen Pharmaceuticals, Inc.

Lara Gray disclosed no relevant financial relationships with any commercial interests.

UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME or Imedex.

Privacy Policy

NACCME and Imedex protect the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME, Imedex and our joint providers will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME and Imedex maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2019 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.